Cargando…

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.

The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting >...

Descripción completa

Detalles Bibliográficos
Autores principales: Hejna, M., Kornek, G. V., Raderer, M., Depisch, D., Brodowicz, T., Fiebiger, W. C., Scheithauer, W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062977/
https://www.ncbi.nlm.nih.gov/pubmed/9743296
_version_ 1782137241875775488
author Hejna, M.
Kornek, G. V.
Raderer, M.
Depisch, D.
Brodowicz, T.
Fiebiger, W. C.
Scheithauer, W.
author_facet Hejna, M.
Kornek, G. V.
Raderer, M.
Depisch, D.
Brodowicz, T.
Fiebiger, W. C.
Scheithauer, W.
author_sort Hejna, M.
collection PubMed
description The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting > or = 12 weeks after six monthly courses of first-line treatment with 5-fluorouracil + racemic leucovorin (5-FU/LV; n = 35) or 5-FU plus the l-isomer of LV (LLV; n = 34) were entered in this study. At the time of relapse, the same treatment was used for initial therapy: racemic LV or LLV was administered at 100 mg m(-2) day(-1) by i.v. bolus injection, immediately followed by 5-FU 400 mg m(-2) day(-1) given as a 2-h infusion. Chemotherapeutic drugs were given on 5 consecutive days at 4-week intervals x 6 or until there was evidence of tumour progression. Among 49 evaluable patients, reinduction therapy that was initiated after a median treatment-free interval of 5.4 months (range 3-14.5) resulted in nine partial response (PR) (18%) and 26 stable disease (SD) (53%), yielding an overall tumour control rate of 69% (95% confidence interval, 54.6-81.7%). The median time to treatment failure from reinduction was 6.4 months, and the median survival duration from reinduction was 8.9 months (20.1 months as judged from the beginning of induction therapy). The toxicity associated with retreatment was generally mild to moderate; compared with initial treatment, there was no significant difference in terms of the overall rate (P = 0.33) or severity (P = 0.19) of adverse reactions. Our data suggest that in patients with advanced colorectal cancer an interrupted treatment strategy, i.e. retreatment with the same regimen in case of relapse > or = 3 months after discontinuation of 6 months of successful treatment with 5-FU/LV or 5-FU/LLV is an acceptable therapeutic concept.
format Text
id pubmed-2062977
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20629772009-09-10 Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Hejna, M. Kornek, G. V. Raderer, M. Depisch, D. Brodowicz, T. Fiebiger, W. C. Scheithauer, W. Br J Cancer Research Article The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved stable disease lasting > or = 12 weeks after six monthly courses of first-line treatment with 5-fluorouracil + racemic leucovorin (5-FU/LV; n = 35) or 5-FU plus the l-isomer of LV (LLV; n = 34) were entered in this study. At the time of relapse, the same treatment was used for initial therapy: racemic LV or LLV was administered at 100 mg m(-2) day(-1) by i.v. bolus injection, immediately followed by 5-FU 400 mg m(-2) day(-1) given as a 2-h infusion. Chemotherapeutic drugs were given on 5 consecutive days at 4-week intervals x 6 or until there was evidence of tumour progression. Among 49 evaluable patients, reinduction therapy that was initiated after a median treatment-free interval of 5.4 months (range 3-14.5) resulted in nine partial response (PR) (18%) and 26 stable disease (SD) (53%), yielding an overall tumour control rate of 69% (95% confidence interval, 54.6-81.7%). The median time to treatment failure from reinduction was 6.4 months, and the median survival duration from reinduction was 8.9 months (20.1 months as judged from the beginning of induction therapy). The toxicity associated with retreatment was generally mild to moderate; compared with initial treatment, there was no significant difference in terms of the overall rate (P = 0.33) or severity (P = 0.19) of adverse reactions. Our data suggest that in patients with advanced colorectal cancer an interrupted treatment strategy, i.e. retreatment with the same regimen in case of relapse > or = 3 months after discontinuation of 6 months of successful treatment with 5-FU/LV or 5-FU/LLV is an acceptable therapeutic concept. Nature Publishing Group|1 1998-09 /pmc/articles/PMC2062977/ /pubmed/9743296 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hejna, M.
Kornek, G. V.
Raderer, M.
Depisch, D.
Brodowicz, T.
Fiebiger, W. C.
Scheithauer, W.
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title_full Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title_fullStr Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title_full_unstemmed Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title_short Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
title_sort reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062977/
https://www.ncbi.nlm.nih.gov/pubmed/9743296
work_keys_str_mv AT hejnam reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT kornekgv reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT radererm reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT depischd reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT brodowiczt reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT fiebigerwc reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer
AT scheithauerw reinductiontherapywiththesamecytostaticregimeninpatientswithadvancedcolorectalcancer